Kazia Therapeutics Announced The Early Conclusion Based On Safety And Clinical Response Findings Observed To Date From A Two-part Phase 1 Trial Of Paxalisib With Radiation Therapy For PI3K Pathway Mutation Brain Metastases From Solid Tumors
Kazia Therapeutics Announced The Early Conclusion Based On Safety And Clinical Response Findings Observed To Date From A Two-part Phase 1 Trial Of Paxalisib With Radiation Therapy For PI3K Pathway Mutation Brain Metastases From Solid Tumors
Kazia Therapeutics根據迄今爲止在一項由兩部分組成的Paxalisib的1期試驗中觀察到的安全性和臨床反應結果宣佈了早期結論，該試驗採用了針對實體瘤的PI3K途徑突變腦轉移的放射治療
Kazia Therapeutics Announced The Early Conclusion Based On Safety And Clinical Response Findings Observed To Date From A Two-part Phase 1 Trial Of Paxalisib With Radiation Therapy For PI3K Pathway Mutation Brain Metastases From Solid Tumors
Kazia Therapeutics根據迄今爲止在一項由兩部分組成的Paxalisib的1期試驗中觀察到的安全性和臨床反應結果宣佈了早期結論，該試驗採用了針對實體瘤的PI3K途徑突變腦轉移的放射治療
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。